JPM 2026 Deck - PTCT - 1.9.26-FINAL - PDF.pdf

1、J.P.Morgan 2026 Healthcare ConferencePTC Therapeutics 2026Matthew B.Klein,MDCEO J.P.Morgan 2026 Healthcare ConferenceJ.P.Morgan 2026 Healthcare ConferenceFDA and EMA approvals of SephienceAdvancement of early-stage R&D programs Strong start to Sephience global launchDrive revenue and effectively man

2、age OpEx2025:A Year of Focus and Execution2J.P.Morgan 2026 Healthcare ConferenceJ.P.Morgan 2026 Healthcare ConferenceThis presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.All statements contained in this presentation,other th

3、an statements of historic fact,are forward-looking statements,including statements with respect to 2026 total product revenue guidance and 2026 operating expense guidance,and statements regarding:the future expectations,plans and prospects for PTC,including with respect to the expected timing of cli

4、nical trials and studies,availability of data,regulatory submissions and responses,meetings with regulatory agencies,commercialization and other matters with respect to its products and product candidates;PTCs strategy,future operations,future financial position,future revenues,projected costs;and t

5、he objectives of management.Other forward-looking statements may be identified by the words,guidance,plan,anticipate,believe,estimate,expect,intend,may,target,potential,will,would,could,should,continue,aim,and similar expressions.PTCs actual results,performance or achievements could differ materiall

6、y from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties,including those related to:the outcome of pricing,coverage and reimbursement negotiations with third party payors for PTCs products or product candidates that PTC commercializ